INTRAVENOUS (IV) IBUPROFEN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global intravenous (IV) ibuprofen market is estimated to be valued at USD 6.91 Bn in 2024 and is expected to exhibit a CAGR of 7% during the forecast period (2024-2031). Intravenous (IV) ibuprofen is used for pain relief and fever reduction for several decades. As an intravenous formulation of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, it offers faster absorption and onset of action as compared to oral administration. Intravenous (IV) ibuprofen works by blocking the production of prostaglandins - hormone-like substances in the body that promote pain and fever. With intravenous delivery, it can provide relief for moderate to severe pain within 15 minutes and may be effective for up to 8 hours with a single dose. Global intravenous (IV) ibuprofen market has witnessed steady growth in recent years due to increasing prevalence of diseases requiring IV pain management and benefits over other analgesic options.

Market Dynamics:

Global intravenous (IV) ibuprofen market growth is driven by rising geriatric population suffering from orthopedic diseases and postoperative pain, growing prevalence of fever and pain conditions, and superior efficacy of IV ibuprofen over oral NSAIDs. However, potential risks of gastrointestinal bleeding and kidney toxicity with long-term use along with preference for non-opioid alternatives are expected to restrain the market growth. Ongoing clinical trials evaluating efficacy for new indications and formulations present lucrative opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global intravenous (IV) ibuprofen market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global intravenous (IV) ibuprofen market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, and Hikma Pharmaceuticals PLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global intravenous (IV) ibuprofen market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global intravenous (IV) ibuprofen market.

Detailed Segmentation-

• By Indication:
  • Pain Management
  • Fever
  • Others
• By Strength:
  • 100 mg
  • 200 mg
  • 400 mg
  • 800 mg
• By Age Group:
  • Pediatrics
  • Adults
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Cumberland Pharmaceuticals Inc. 
  • Hyloris Pharmaceuticals SA
  • Grifols, S.A.
  • Recordati Rare Diseases Inc.
  • XGEN PHARMACEUTICALS DJB, Inc.
  • AFT Pharmaceuticals
  • Laboratorios Valmorca
  • SGPharma Pvt. Ltd.
  • Wellona Pharma
  • Delex Pharma
  • Hikma Pharmaceuticals PLC